What is Multiple Sclerosis (MS)?
Multiple Sclerosis (MS) is a complex neurological condition that affects the brain and spinal cord, often causing a wide range of symptoms including fatigue, mobility challenges, vision problems and cognitive changes. Over 150,000 people live with the condition in the UK1.
Is there a cure for Multiple Sclerosis (MS)?
Although there is currently no cure, decades of research have led to significant advances in treatment and care. Today, doctors and scientists are building on these discoveries to develop therapies that not only manage symptoms and slow disease progression but potentially repair damage caused by the condition.
What causes Multiple Sclerosis?
The exact cause of MS is unknown, but it is widely understood as an autoimmune disease where the immune system mistakenly attacks the protective sheath (myelin) covering nerve fibres in the brain and spinal cord. This damage disrupts communication between the brain and the rest of the body, leading to the symptoms associated with the condition.
Because MS affects people differently, understanding the underlying biology of the disease is critical. Research helps scientists uncover why MS develops, how it progresses, and what factors influence disease activity. Every new discovery provides valuable insight that could lead to more effective treatments and improved outcomes for people living with MS.
New treatments for Multiple Sclerosis
One of the most significant achievements in MS research has been the development of disease-modifying therapies (DMTs). These treatments have transformed care for many people with relapsing forms of MS by reducing relapse rates and slowing progression.
Researchers continue to explore new approaches that target the immune system more precisely. However, DMTs can also cause side effects, including an increased risk of infections, with risks varying depending on the treatment.
As our understanding of genetics, immunology and disease mechanisms grows, the future of treatment is becoming increasingly personalised. Researchers hope that one day clinicians will be able to predict how a patient’s MS is likely to progress and select the most appropriate treatment from the outset.
Early Detection of MS
Another important area of research involves identifying biomarkers, measurable indicators that provide information about disease activity and progression.
Advances in blood testing and imaging technology may help healthcare professionals detect subtle changes in disease activity earlier than before. This is particularly important in the UK, where around 8 to 11 new cases are diagnosed per 100,000 people each year2. Earlier detection can support faster treatment decisions and help clinicians monitor how well therapies are working, creating opportunities for more responsive and effective care.
Developing New MS Treatments
At the heart of every medical breakthrough is clinical research. Clinical trials play a vital role in advancing our understanding of MS and evaluating potential new treatments.
These studies help researchers assess whether new interventions are safe and effective, while also providing valuable insights into the condition itself.
Importantly, the progress seen in MS treatment over the last few decades would not have been possible without the participation of people living with the condition. Every clinical trial contributes to a growing body of evidence that helps shape future standards of care.
As research continues to evolve, clinical trials remain the bridge between scientific discovery and real-world treatment. They offer hope for more effective therapies, better quality of life and, ultimately, a future where MS can be stopped, repaired or even prevented altogether. Through continued innovation and participation in research, the outlook for people affected by MS has never been more promising.
MAC Clinical Research is looking for people who would like to take part in a clinical trial at their Greater Manchester clinic, researching a potential new treatment for Multiple Sclerosis. If you are aged 18-65 and living with MS, you may be eligible to take part. For more information, please visit MAC Clinical Research’s MS webpage.
Doctor Chloe Theodorou, Clinical Research Physician at MAC Clinical Research said: “Our priority is for everyone taking part in this MS trial to feel listened to, informed and supported. We’re here to answer questions and put participants’ wellbeing first throughout their time with us.”
If eligible, you may be compensated for your time and commitment plus reasonable travel expenses will be reimbursed or transport provided.
1 MS Society – MS in the UK
2 Public Health England – Multiple sclerosis: prevalence, incidence and smoking status – data briefing
